NLS Pharmaceutics Ltd

NLSP

Company Profile

  • Business description

    NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

  • Contact

    The Circle 6
    Zurich8058
    CHE

    T: +41 445122150

    E: [email protected]

    https://www.nlspharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    250

Stocks News & Analysis

stocks

Signs of a turnaround for undervalued ASX share

Market likes the payoff from early efforts at reining in costs.
stocks

Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?

Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
stocks

Investing in gold miners

Exploring the commodity as prices continue to soar. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,825.1020.900.24%
CAC 408,178.5414.430.18%
DAX 4022,513.4298.60-0.44%
Dow JONES (US)44,546.08165.35-0.37%
FTSE 1008,732.4632.26-0.37%
HKSE22,620.33805.963.69%
NASDAQ20,026.7781.130.41%
Nikkei 22539,149.43312.04-0.79%
NZX 50 Index12,989.1883.200.64%
S&P 5006,114.630.44-0.01%
S&P/ASX 2008,555.8015.800.19%
SSE Composite Index3,346.7214.240.43%

Market Movers